Doug Ingram, Sarepta CEO (Sarepta)
September 10, 2020 07:07 AM EDT
R&D
FDA+

FDA knocks back Sarep­ta in Duchenne gene ther­a­py race with Pfiz­er, but an­a­lysts urge cau­tion

Jason Mast

Editor

Sarep­ta has gone all-in on gene ther­a­py over the last few years, rac­ing with Pfiz­er and Sol­id Bio­sciences to be the first to de­vel­op a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times